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LONG TERM COMPLIANCE WITH 
ANTIHYPERTENSIVE DRUG THERAPY IN A 
MANAGED CARE ORGANIZATION
 
Simons R
 
Millennium Biostatistics & Health Economics, Millburn, NJ, USA
 
Evidence is accumulating that long term compliance (LTC)
may be better with newer antihypertensive agents that have
better safety profiles.
 
OBJECTIVES:
 
 To evaluate whether newer, better tolerated
drugs improve LTC with antihypertensive medications.
 
METHODS:
 
 We used pharmacy and healthcare adminis-
trative claims data from United Healthcare (1994–1997)
to compare retrospectively LTC by antihypertensive drug
class. The study population consisted of hypertensive pa-
tients on monotherapy from six U.S. HMOs, and enrolled
in the plan for the duration of the 18 months of follow up.
We assessed patients on diuretics, beta-blockers (BB),
CCBs, ACEs, and ARBs. We estimated a two-stage model
that measures LTC by drug class while adjusting for physi-
cian’s decisions to select a particular drug due to the pa-
tient’s medical history. Logistic regressions were used first
to estimate physician’s prescribing decisions based on the
patient’s medical profile. Second, Cox regression was used
to estimate LTC for each drug class while controlling for
physician’s choices, plan type, HMO geographic location,
and patient demography.
RESULTS: The study entry criteria provided for analysis
of 9,002 patients with mean age of 54 years and 52%
male. By drug, patients were distributed as diuretics 342
(3.7%), BB 316 (3.5%), ACEs 3516 (39.0), CCBs 4514
(50.1%), and ARBs 314 (3.4%). LTC was significantly
better for patients treated with ACEs and CCBs compared
to diuretics and BB (61% vs 37% at 1 yr). ARBs showed
the most favorable LTC (90% at 1 yr). The log rank tests
indicated that LTC were statistically different (better) for
patients treated with ACEs and CCBs compared to diuret-
ics and BB (p  0.001) and statistically different (better)
for patients treated with ARBs compared to ACEs and
CCBs (p  0.001).
CONCLUSION: These results indicate that choice of anti-
hypertensives plays an important role in LTC and newer
agents with improved tolerability like ARBs provided the
best LTC.
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OJECTIVES:
 
 To assess the relative cost-efficacy of low-
molecular-weight heparin thromboprophylaxis using dalte-
parin continued beyond hospitalization and warfarin during
hospitalization in patients undergoing total hip replace-
ment (THR) surgery.
METHODS: Patients in this double blind, multi-center
clinical trial received either initial (P1) or extended (P2)
thromboprophylaxis post arthroplasty. P1 patients were
randomized to receive dalteparin pre-operatively (Dpre),
dalteparin post-operatively (Dpost), or warfarin (Warf) for
6  2 days. In P2, patients continued with dalteparin (Dpre,
Dpost) or placebo (Warf) through 35  2 days. Economic
outcomes were based on medical interventions associated
primarily with suspected deep vein thrombosis (DVT) and/
or symptoms of pulmonary embolism (PE) with onset dur-
ing the study. Total inpatient length of stay (LOS) was in-
cluded in calculations of total costs. The thromboprophy-
laxis treatment regimen and a composite intervention for
all major events were valued based on local resource costs.
These costs were then applied to specific patient cases.
RESULTS: A total of 425 patients in the United States
(U.S.) and 705 patients in Canada were in P1; 93 U.S. and
532 Canadian patients continued to P2. The incidence of
suspected DVT was higher in the Warf group in P1 and P2
(p  .002; p  .001). No differences were detected in
LOS. In P1 and P2 respectively, more dalteparin patients
received blood transfusions (p  .001; p  .001). Overall
per patient costs (U.S. dollars) were similar in P1 (Dpre 
$6667, Dpost  $6467, Warf  $6339) and in P2 (Dpre 
$6060, Dpost  $5976, Warf  $5718). Incremental cost-
efficacy for dalteparin ranged (in U.S. dollars) from $1799
to $4661. An analysis by country yielded similar results.
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CONCLUSIONS:
 
 Despite the higher acquisition cost,
thromboprophylaxis with dalteparin is cost-efficacious ver-
sus warfarin in preventing DVT after THR.
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A COST COMPARISON STUDY OF AMLODIPINE 
AND ENALAPRIL AS TREATMENT FOR 
HYPERTENSION IN THE UNITED STATES
Doyle J, Arikian S, Casciano J, Amsel A, Casciano R
The Analytica Group, New York, NY, USA
OBJECTIVES: To compare the cost-effectiveness for treat-
ment of mild and moderate hypertension using either am-
lodipine or enalapril in the United States. The study is
based on data from a randomized controlled clinical trial,
conducted with 461 patients.
METHODS: We used the raw data from a one-year,
double blind clinical trial of amlodipine versus enalapril
to quantify the treatment dosages associated with each
patient group. The amlodipine group consisted of 231
patients, and the enalapril group included 230 patients.
Within the clinical trial, there were no between group sig-
nificant differences for age, gender, concomitant medica-
tions and current illness at randomization. Mean dosages
of amlodipine and enalapril, as well as the frequency and
dosage of diuretic use, were calculated between groups
based on age, gender and study phase, and were used to
estimate the cost of treatment. Efficacy and adverse event
rates were also calculated for each group to compare the
outcomes of the therapy.
RESULTS: Amlodipine ($551.62 per patient annual drug
treatment cost) was less expensive in treating the hyper-
tensive patients within the study as compared to enalapril
($663.48 per patient annual drug treatment cost). Fur-
thermore, a drug price sensitivity test found that with as
much as a 17% reduction in the cost of enalapril, amlo-
dipine would remain a lower or equivalent treatment in
terms of cost. The mean final visit dose amounts of drug
per patient were 7.2 mg/day for amlodipine, and 28 mg/
day enalapril. The total reduction in sitting DBP was
16.9 mmHg with amlodipine and 16.2 mmHg with enal-
april. However, significantly (p  0.05) more patients in
the enalapril group (n  46, 20%) required the use of a
diuretic (HCTZ) to attain control of DBP than in the am-
lodipine group (n  27, 11.7%). Finally, there were no
significant differences (p  0.05) in adverse events be-
tween groups (amlodipine  21.2%; enalapril  17.4%).
Yet, the type of adverse event differed by drug where a
significant effect (p  0.001) of amlodipine and edema
(15.2%) was found, and a significant effect (p  0.001)
for enalapril and cough (7.4%) was found.
CONCLUSION: This study suggests that amlodipine is a
less costly therapy compared to enalapril, and hence a
potentially more cost-effective treatment for mild and
moderate hypertension.
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OBJECTIVE:
 
 Evaluation of the economic impact of hy-
pertension and its correlates.
 
METHODS:
 
 Twenty-seven GPs and 9 specialist centers
participated in this longitudinal study. Information on
lifestyle, SBP, DBP, comorbidities, diagnostic and lab ex-
ams, hospitalizations, physician’s visits, drug and medical
therapies was collected. We report on healthcare costs
(hospitalizations excluded), quantified in the perspective
of the Italian National Health Service (NHS), by means
of tariffs expressed in Italian Lire 1998, and referred to a
three-month period. We used multivariate linear regres-
sion to investigate the association between healthcare
costs, drug cost (or proper transformations) and the level
of SBP and DBP. P  0.05 were considered statistically
significant.
RESULTS: 416 patients were assessed, 210 women (mean
age 63  15) and 206 men (61  12). The mean levels of
SBP and DBP were 149  11 and 90  9 mmHg for men
and 149  15 and 88  9 mmHg for women. The total
three months cost of hypertension care was Lit 294.221
for men and Lit 253.938 for women (NS, Mann Whitney
U test). Drugs represented the largest part of costs (58%),
possibly due to the short time span. We found that new
patients tend to be less costly (P  0.006). Patients en-
rolled by specialists centers (P  0.001); patients with co-
morbidities (P  0.001); smokers (P  0.002) and previ-
ously hospitalized patients were more costly (P  0.001).
No influence of age and sex was detected. The health care
cost of hypertension was associated with the level of SBP
(P  0.007) and DBP (P  0.001). The cost of drug ther-
apy was significantly higher in patients with higher SBP
and DBP levels (P  0.001 and P  0.005 respectively).
DISCUSSION: Hypertension is a quite costly disease.
Healthcare costs of hypertension and the costs of anti-
hypertensive drug therapy are associated with the level
both of SBP and DBP. Interventions effective in controlling
SBP and DBP are likely to affect costs.
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